Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 19 of 19 for “"Factor IX (FIX)"”.

  1. In Vitro Binding and Transport Regulation by Endothelial Cells: Preliminary Studies looking at FIX and IGF-I

    … study investigates how the recombinant source of Factor IX (FIX), a blood coagulant protein used in the treatment of Hemophilia B, impacts surface ligand binding (FIX to its specific receptors) to bovine aortic endothelial cells (BAECs). Competitive binding experiments between 125I-FIX and FIX …

    vt Repository record for In Vitro Binding and Transport Regulation by Endothelial Cells: Preliminary Studies looking at FIX and IGF-I (opens in a new tab)

  2. ENCAPSULATION OF FACTOR IX-ENGINEERED MESENCHYMAL STEM CELLS IN ALGINATE-BASED MICROCAPSULES FOR ENHANCED VIABILITY AND FUNCTIONALITY

    … mimic their physiological extracellular matrix (ECM) environment.</p> <p>Three cell-adhesive molecules were used in this work: fibrinogen and fibronectin, two abundant proteins present in ECM, and arginine-glycine-aspartic acid (RGD) tri-peptide, the minimal essential cell adhesion peptide …

    mcmaster Repository record for ENCAPSULATION OF FACTOR IX-ENGINEERED MESENCHYMAL STEM CELLS IN ALGINATE-BASED MICROCAPSULES FOR ENHANCED VIABILITY AND FUNCTIONALITY (opens in a new tab)

  3. Using Metabolic and Genetic Engineering to Develop Novel Cell Platforms for the Production of Recombinant Glycoproteins with Enhanced Pharmacokinetic Properties

    … a CHO cell line producing the coagulation factor IX (FIX) with “humanized” sialylation and an augmented serum half-life. A CHO cell line expressing ST6GAL1, a sialyltransferase found in humans but naturally silent in CHO cells, and producing FIX was successfully created. FIX will provide an …

    jhu Repository record for Using Metabolic and Genetic Engineering to Develop Novel Cell Platforms for the Production of Recombinant Glycoproteins with Enhanced Pharmacokinetic Properties (opens in a new tab)

  4. The metal dependency of coagulation factor IX as it relates to its structure and function

    … disorder caused by deficiency in blood clotting factor IX (FIX). FIX circulates as a 55–57 kDa inactive precursor of the serine protease, FIXa. Activation results in the release of the activation peptide to generate an amino terminal light chain of Mr∼18,000 and a carboxyl terminal heavy chain of …

    nebraska Repository record for The metal dependency of coagulation factor IX as it relates to its structure and function (opens in a new tab)

  5. Gene Therapy Approaches To Immune Tolerance Induction In Canine Hemophilia

    … of severe hemophilia B to express a hyperactive factor IX (FIX) variant from skeletal muscle via adeno-associated viral (AAV) vector and observed curative levels of expression that lasted for >3 years (ongoing observation). There was no evidence of an immune response even after immunological …

    penn Repository record for Gene Therapy Approaches To Immune Tolerance Induction In Canine Hemophilia (opens in a new tab)

  6. Canadian Hemophilia Carriers Pregnancy Study: Coagulation Factor Levels and Postpartum Blood Loss

    … bleeding disorder caused by a deficiency in Factor VIII (FVIII) or Factor IX (FIX) that was previously thought to only affect men. Women are carriers for this disorder with recent studies showing that they may also be affected by hemophilia. In recent years, it has been consistently reported …

    queens Repository record for Canadian Hemophilia Carriers Pregnancy Study: Coagulation Factor Levels and Postpartum Blood Loss (opens in a new tab)

  7. Evaluation of the determinants and characterization of bleeding in hemophilia A and B carriers

    … disorders caused by a deficiency in coagulation factor VIII (FVIII) or coagulation factor IX (FIX), respectively. Due to the X-linked inheritance pattern, males are affected with the disease, while females are almost exclusively carriers of hemophilia. Although carriers were historically assumed …

    queens Repository record for Evaluation of the determinants and characterization of bleeding in hemophilia A and B carriers (opens in a new tab)

  8. Novel carriers for oral delivery of hemophiliac factor IX

    … characterized by the deficiency of coagulation factor IX (FIX), rely on injection-based administration that cause pain and discomfort, leading to noncompliance and risk of subsequent bleeding episodes. A non-invasive protein replacement therapy using an oral delivery system can both overcome …

    texas Repository record for Novel carriers for oral delivery of hemophiliac factor IX (opens in a new tab)

  9. Building multiplexed genomic tools for editing and interpreting human variation

    … display. I apply this method to coagulation factor IX (FIX), the primary genetic cause of hemophilia B, to quantify variant effects on FIX secretion, identify structural constraints for folding and secretion, and apply these data to FIX variation to determine mechanisms of disease. I then …

    washington Repository record for Building multiplexed genomic tools for editing and interpreting human variation (opens in a new tab)

  10. Investigating the Human-mouse Interspecies Barrier to AAV-driven Gene Therapy Using a Mouse with a Humanized Liver

    … humans. Clinical trials using rAAV8 to deliver factor IX (FIX) gene demonstrated much lower plasma FIX levels in human patients than that shown in rodents and non-human primates (NHPs). In contrast, AAV5-mediated expression of B-domain deleted Factor VIII translated relatively well from …

    dominican Repository record for Investigating the Human-mouse Interspecies Barrier to AAV-driven Gene Therapy Using a Mouse with a Humanized Liver (opens in a new tab)

  11. Production of recombinant human coagulation factor IX by transgenic pig

    … caused by deficiency in functional coagulation factor IX (FIX) and about 28,000 patients worldwide in 2012. And current treatment is restricted to protein-replacement therapy, which required FIX concentrates for patients' life-time. Approximately 1 billion units FIX were consumed in 2012. …

    nebraska Repository record for Production of recombinant human coagulation factor IX by transgenic pig (opens in a new tab)

  12. CHITOSAN-MEDIATED ORAL GENE THERAPY FOR HEMOPHILIA TREATMENT AND PROPHYLACTIC TOLERANCE

    … caused by the deficiency of coagulation factor VIII (FVIII) and Factor IX (FIX), respectively. Current treatment involves life-long protein replacement therapy which is invasive, expensive and inaccessible to the majority of hemophiliacs worldwide. Treatment is further compromised by the …

    mcmaster Repository record for CHITOSAN-MEDIATED ORAL GENE THERAPY FOR HEMOPHILIA TREATMENT AND PROPHYLACTIC TOLERANCE (opens in a new tab)

  13. The N-terminal EGF Module of Coagulation factor IX. Studies of Calcium Binding and Module Interactions.

    Coagulation factor IX (FIX) is a vitamin K-dependent serine protease zymogen that circulates in plasma. Defects in FIX cause the bleeding disorder hemophilia B. FIX contains a Gla module, two Epidermal Growth Factor (EGF) -like modules and a serine protease region. In this thesis, studies have been …

    lund Repository record for The N-terminal EGF Module of Coagulation factor IX. Studies of Calcium Binding and Module Interactions. (opens in a new tab) Download PDF for The N-terminal EGF Module of Coagulation factor IX. Studies of Calcium Binding and Module Interactions. (opens in a new tab)

  14. Development of a gene targeting strategy for liver metabolic diseases using the Crispr/Cas9 platform

    … by the non-functionality of the coagulation factor 9 (FIX), produced by hepatocytes, leading to a deficient clotting activity and frequent spontaneous bleeding episodes. Both disorders require life-long treatments and, in the case of CTLN1, liver transplantation remains the only permanent …

    trento Repository record for Development of a gene targeting strategy for liver metabolic diseases using the Crispr/Cas9 platform (opens in a new tab)

  15. Development of a Liver Gene Therapy Strategy for Haemophilia B With Lentiviral Vectors

    … animal model. Our results show long-term canine Factor IX (FIX) expression up to 0.5-1% of normal levels and clinical improvement (almost complete prevention of spontaneous bleedings) in two haemophilia B dogs (>3.5 years cumulative follow up), with mild acute toxicity and without long-term …

    the-open-u Download PDF for Development of a Liver Gene Therapy Strategy for Haemophilia B With Lentiviral Vectors (opens in a new tab)

  16. Haemophilia B - Diagnostic Insights, Genetic Aspects and Clinical Outcomes

    … disorder caused by the deficiency of coagulation factor IX (FIX). The major clinical issues are bleedings, often targeting the joints, and the development of neutralising antibodies, i.e. inhibitors, to the FIX replacement therapy. Historically HB has been seen as identical to the more common …

    lund Repository record for Haemophilia B - Diagnostic Insights, Genetic Aspects and Clinical Outcomes (opens in a new tab) Download PDF for Haemophilia B - Diagnostic Insights, Genetic Aspects and Clinical Outcomes (opens in a new tab)

  17. Mutation Analysis in Haemophilia A and Investigation of a Keratinocyte Based Gene Therapy for Haemophilia B

    … of the procoagulant function of clotting factors VIII and IX in the intrinsic coagulation pathway, respectively. The two main objectives of this project were: (I) to carry out a comprehensive search for mutations in the factor VIII gene of patients with haemophilia A and (II) to …

    glasgow Download PDF for Mutation Analysis in Haemophilia A and Investigation of a Keratinocyte Based Gene Therapy for Haemophilia B (opens in a new tab)

  18. Characterization of Post-translational Modifications and Resulting Structure/Function Relationships of Recombinant Human Factor IX Produced in the Milk of Transgenic Pigs

    … caused by a deficiency in or dysfunction of factor IX (FIX), a complex plasma glycoprotein required for the formation and maintenance of blood clots. Treatment of hemophilia B involves infusion of replacement FIX currently derived from two sources: FIX purified from pools of human plasma …

    vt Repository record for Characterization of Post-translational Modifications and Resulting Structure/Function Relationships of Recombinant Human Factor IX Produced in the Milk of Transgenic Pigs (opens in a new tab)

  19. Nonviral vector strategies for ultrasound targeted microbubble destruction-mediated hepatic gene therapy

    … We measured reporter and human blood coagulation factor IX transgene expression in the mouse liver and plasma driven by constitutive and tissue-specific promoters. In vitro we demonstrated a ten-fold increase in the level of reporter expression in HEK293 cells after transfection with a piggyBac …

    hawaii Repository record for Nonviral vector strategies for ultrasound targeted microbubble destruction-mediated hepatic gene therapy (opens in a new tab)